UBS lowered the firm’s price target on Cabot (CBT) to $83 from $93 and keeps a Neutral rating on the shares. The firm sees another challenging earnings cycle, with “largely ok” downstream earnings, while upstream/commodity earnings will be impacted by higher costs and likely weaker end of quarter demand, the analyst tells investors in a research note. UBS sees earnings misses to drive stocks down vs. provide relief.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBT: